Revolution Medicines (RVMD) Accounts Payables (2019 - 2026)

Revolution Medicines has reported Accounts Payables for 8 years, with the latest figure at $80.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 69.53% year-over-year to $80.5 million; the trailing twelve-month figure through Mar 2026 stood at $80.5 million (up 69.53% YoY), and the FY2025 full-year result was $64.6 million, up 18.72% from the prior year.
• Accounts Payables for Q1 2026 stood at $80.5 million, up from $64.6 million in the prior quarter.
• The five-year high for Accounts Payables was $80.5 million in Q1 2026, with the low at $14.1 million in Q2 2022.
• Average Accounts Payables over 5 years is $40.0 million, with a median of $29.8 million recorded in 2023.
• Year-over-year, Accounts Payables decreased 17.45% in 2024 and jumped 206.06% in 2025.
• Tracing RVMD's Accounts Payables over 5 years: stood at $21.3 million in 2022, then soared by 190.0% to $61.8 million in 2023, then declined by 11.91% to $54.4 million in 2024, then increased by 18.72% to $64.6 million in 2025, then increased by 24.64% to $80.5 million in 2026.
• The last three Accounts Payables figures came in at $80.5 million (Q1 2026), $64.6 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.

Peer Comparison